Pharmaceutical stocks are some of the biggest in the FTSE 100. The sector is threatened by tariffs, but some have posted encouraging results regardless.

Dan Lefkovitz of Morningstar I recently interviewed investor and author Daniel Rasmussen for The Long View podcast, where he ...

AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca PLC (NASDAQ:AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) announced ...

AstraZeneca's strategic $50B investment promises to revolutionize U.S. medicine production with advanced manufacturing and ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D) ...

The announcement by AstroZeneca follows a growing trend of companies pledging to invest in pharmaceutical manufacturing on ...

American companies in China are reporting record-low investment plans and declining confidence in profits this year.